Fairvalue-Calculator Fairvalue-Calculator
EN DE

Duopharma Biotech Berhad, (7148) Fair Value & Analysis

Healthcare · MY · Market cap 1.2B MYR

Price1.22 MYR
Fair Value2.00 MYR
Upside+63.9%
Quality95/100
Evidence: High Range 1.16 MYR – 2.50 MYR

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Duopharma Biotech Berhad, (7148) currently trades at 1.22 MYR, while our model-based Fair Value estimate is 2.00 MYR — implying the stock looks roughly 63.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives under the Uphamol, Uphacol, and Uphaplast brand names; eyecare products under the Eye Glo brand name; antacids under the Alucid brand name; joint pain products under the Donna brand name; skincare products under Dermoplex brand name; cosmeceuticals under the IRORO Nutreatment brand name; and functional food under the CHAMPS Nutribar and PROVITON STR Powerz brand names. The company also provides generic drugs for various therapeutic areas, such as cardiovascular, dermatology, hormonal, respiratory, sensory and nervous system, musculoskeletal, anti-infectives, and others; and specialty pharma…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -81%

Frequently asked questions

Is Duopharma Biotech Berhad, (7148) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 2.00 MYR versus a price of 1.22 MYR — about +64% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 7148?
Our 21-model fair value for Duopharma Biotech Berhad, is 2.00 MYR (as of Jun 24, 2026), built from audited fundamentals. The current price is 1.22 MYR.
What is the quality score of 7148?
Duopharma Biotech Berhad, has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.